Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Roche Slammed With Partial Holds for Two Combo Cancer Trials

Two Roche drugs were placed on partial clinical hold as the U.S. FDA continues to examine potential dangers of checkpoint inhibitors following deaths associated with Merck’s Keytruda.

Read More »

Patient Deaths Prompt the FDA to Suspend Three of Merck & Co.’s Keytruda Trials

FDA placed a clinical hold on three trials studying Merck’s PD-1 inhibitor Keytruda in combination with products developed by Celgene following Merck’s initial reporting of several patient deaths.

Read More »

Deaths Force Merck & Co. to Halt Enrollment for Blood Cancer Studies

Merck & Co. halted two Phase III multiple myeloma trials testing the company’s blockbuster anti-PD-1 drug Keytruda after an external monitoring committee expressed concern over trial patient deaths in the groups taking the drug.

Read More »

Celgene Accused of ‘Scheme to Gain Billions’

Allegations were made that Celgene donated millions of dollars to charities that help patients afford high-priced cancer drugs as part of a profit-making scheme.

Read More »

2016 Annual Report: Top 10 Pipelines

The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.

Read More »

FDA approves new Bristol-Myers treatment for multiple myeloma

The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer. The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp’s Revlimid and common anti-inflammatory drug […]

Read More »

DARZALEX (daratumumab) Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of Multiple Myeloma

    First-in-class immunotherapy approved for multiple myeloma patients who have received three or more prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent PR Newswire, HORSHAM, PA, November 16, 2015 Janssen Biotech, Inc., a Janssen Pharmaceutical Company of […]

Read More »

FDA approves J&J drug for advanced multiple myeloma

U.S. regulators have approved an experimental treatment from Johnson & Johnson that may offer hope to multiple myeloma patients who have run out of other options against the blood cancer. The U.S. Food and Drug Administration on Monday said it had approved Darzalex (daratumumab) for patients who had already undergone at least three prior standard […]

Read More »

Spectrum says FDA declines to approve Evomela for injection

Biotechnology company Spectrum Pharmaceuticals Inc said the U.S. Food and Drug Administration declined to approve its Evomela injection to treat patients with multiple myeloma, a form of blood cancer that arises from plasma cells found in bone marrow. Spectrum Pharmaceuticals said it received a complete response letter, which the FDA sends to let a drug […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom